FDA, Gene Therapy and Pfizer
The drug-pricing watchdogs over at the Institute for Clinical and Economic Review tend to be supportive of gene therapy ...
The chief medical officer of a drug pricing watchdog is warning against the FDA granting full approval to drugs that were previously granted accelerated approval if they then go on to fail ...
XC001 is designed to transiently grow new blood vessels to restore blood flow in the heart. It contains alternative splicing of the three isoforms of VEGF-A, which sets it apart from past attempts at ...
Final 12-month data from the EXACT trial demonstrates safety and efficacy results for a vascular endothelial growth factor ...
More than 20 years of gene therapy clinical research have led to etranacogene dezaparvovec’s use in hemophilia B, according to authors of a recent review—and it takes its place in a line of current ...
Walgreens, one of the largest retail pharmacy companies in the world, announced last week that it plans to launch a variety ...
Sponsored content brought to you by The launch of Revvity, Inc. in May 2023 signaled the rebranding of an 85-year-old company ...
The experimental new approach, delivered to the heart of those with angina after bypass surgery, showed evidence of restored blood flow 1 year later.
Experts hold scalability challenges and high costs accountable for market failures within the cell and gene therapy landscape ...
Federico Mingozzi, PhD, joins Allison Keeler, PhD, on GEN Live to discuss the state of gene therapy and what they are looking forward to at the ASGCT meeting in May.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, announced that Dr. Benjamin Bakall will present ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback